Total Payments
$71,082
2024 Payments
$13,529
Companies
19
Transactions
58
Medicare Patients
774
Medicare Billing
$110,179
Payment Breakdown by Category
Consulting$60,191 (84.7%)
Other$8,520 (12.0%)
Food & Beverage$1,218 (1.7%)
Research$675.28 (0.9%)
Travel$478.71 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $60,191 | 21 | 84.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,520 | 7 | 12.0% |
| Food and Beverage | $1,218 | 25 | 1.7% |
| Unspecified | $675.28 | 2 | 0.9% |
| Travel and Lodging | $478.71 | 3 | 0.7% |
Payments by Type
General
$70,407
56 transactions
Research
$675.28
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $12,229 | 12 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $10,991 | 8 | $0 (2024) |
| Deciphera Pharmaceuticals Inc. | $10,548 | 3 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $9,115 | 9 | $0 (2024) |
| Daiichi Sankyo Inc. | $6,330 | 7 | $0 (2019) |
| Eli Lilly and Company | $5,122 | 3 | $0 (2017) |
| Ipsen Bioscience Inc. | $3,480 | 1 | $0 (2023) |
| Ipsen Biopharmaceuticals, Inc | $3,020 | 1 | $0 (2020) |
| PFIZER INC. | $2,780 | 2 | $0 (2019) |
| Amgen Inc. | $2,596 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,529 | 11 | Boehringer Ingelheim Pharmaceuticals, Inc. ($10,991) |
| 2023 | $18,320 | 7 | Boehringer Ingelheim International GmbH ($7,640) |
| 2022 | $4,175 | 5 | GlaxoSmithKline, LLC. ($1,950) |
| 2021 | $6,796 | 4 | Amgen Inc. ($2,596) |
| 2020 | $3,020 | 1 | Ipsen Biopharmaceuticals, Inc ($3,020) |
| 2019 | $10,349 | 15 | Daiichi Sankyo Inc. ($6,330) |
| 2018 | $9,248 | 7 | Bayer HealthCare Pharmaceuticals Inc. ($7,248) |
| 2017 | $5,645 | 8 | Eli Lilly and Company ($5,122) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,360.00 | General |
| 08/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $140.00 | General |
| 08/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 08/15/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Consulting Fee | Cash or cash equivalent | $2,047.50 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2024 | Exelixis Inc. | — | Food and Beverage | In-kind items and services | $40.82 | General |
| 07/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $115.41 | General |
| 07/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 07/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 07/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $17.42 | General |
| 07/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $243.33 | General |
| 03/28/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 09/20/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 09/20/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 06/15/2023 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 06/09/2023 | Ipsen Bioscience Inc. | — | Consulting Fee | Cash or cash equivalent | $3,480.00 | General |
| 04/13/2023 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $4,230.51 | General |
| 03/23/2023 | Deciphera Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $7,200.00 | General |
| 01/12/2023 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $484.73 | General |
| 10/28/2022 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $209.40 | General |
| 06/30/2022 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $605.91 | General |
| 06/30/2022 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $209.40 | General |
| 05/26/2022 | Medtronic, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 02/17/2022 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 12/17/2021 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug), Stivarga | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Oncology | ||||||
| 12/03/2021 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $2,596.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 ANTI-LAG-3 MAB ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 ANTI-PD-1 MAB IN PATIENTS WITH ADVANCED MALIGNANCIES | Regeneron Pharmaceuticals, Inc. | $675.28 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 213 | 330 | $178,340 | $29,337 |
| 2022 | 6 | 165 | 219 | $41,712 | $19,430 |
| 2021 | 7 | 223 | 390 | $71,054 | $35,295 |
| 2020 | 9 | 173 | 282 | $57,955 | $26,117 |
Total Patients
774
Total Services
1,221
Medicare Billing
$110,179
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 72 | $52,560 | $9,382 | 17.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $44,935 | $6,981 | 15.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 71 | $38,425 | $6,317 | 16.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 45 | 76 | $28,500 | $4,565 | 16.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 26 | 55 | $12,100 | $1,525 | 12.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 13 | $1,820 | $566.02 | 31.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 46 | 75 | $10,900 | $5,574 | 51.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 24 | 33 | $7,395 | $3,854 | 52.1% |
| 99358 | Extended patient service without direct patient contact, first hour | Facility | 2022 | 40 | 41 | $9,881 | $3,690 | 37.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 15 | 15 | $5,325 | $2,287 | 43.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 18 | 18 | $4,770 | $2,060 | 43.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 22 | 37 | $3,441 | $1,965 | 57.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 42 | 104 | $14,685 | $8,133 | 55.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 39 | 62 | $13,640 | $7,710 | 56.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 63 | $11,568 | $5,528 | 47.8% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2021 | 51 | 53 | $12,773 | $4,895 | 38.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 39 | 71 | $6,603 | $3,934 | 59.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 22 | 22 | $7,810 | $3,338 | 42.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 15 | 15 | $3,975 | $1,756 | 44.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 28 | 77 | $13,937 | $6,957 | 49.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 26 | 51 | $11,345 | $4,826 | 42.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 21 | 21 | $7,455 | $2,919 | 39.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 23 | 42 | $5,880 | $2,896 | 49.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 14 | 14 | $4,550 | $2,459 | 54.0% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2020 | 26 | 26 | $6,186 | $2,380 | 38.5% |
About Robert Maki, MD, PHD
Robert Maki, MD, PHD is a Medical Oncology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538130323.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Robert Maki, MD, PHD has received a total of $71,082 in payments from pharmaceutical and medical device companies, with $13,529 received in 2024. These payments were reported across 58 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($60,191).
As a Medicare-enrolled provider, Maki has provided services to 774 Medicare beneficiaries, totaling 1,221 services with total Medicare billing of $110,179. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Pediatrics, Hematology & Oncology
- Location Philadelphia, PA
- Active Since 01/30/2006
- Last Updated 02/02/2021
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1538130323
Products in Payments
- Turalio (Drug) $6,330
- Vitrakvi (Drug) $4,632
- Stivarga (Drug) $3,582
- ONIVYDE (Drug) $3,020
- XALKORI (Drug) $2,780
- QINLOCK (Drug) $2,048
- Nexavar (Drug) $350.00
- FOUNDATIONONE (Device) $85.57
- CYRAMZA (Drug) $67.00
- YONDELIS (Drug) $59.60
- Actemra (Biological) $31.79
- ZEJULA (Drug) $28.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Philadelphia
Daniel Haller, Md, MD
Medical Oncology — Payments: $744,976
Medical Oncology $744,976
Adam Cohen, Md, MD
Medical Oncology — Payments: $302,018
Medical Oncology $302,018
Dr. Jean-Pierre Issa, M.d, M.D
Medical Oncology — Payments: $223,097
Medical Oncology $223,097
Alexander Perl, Md, MD
Medical Oncology — Payments: $218,549
Medical Oncology $218,549
Carl June, Md, MD
Medical Oncology — Payments: $140,824
Medical Oncology $140,824
Anthony Olszanski, M.d, M.D
Medical Oncology — Payments: $131,641
Medical Oncology $131,641